The multifaceted immune regulation of bladder cancer
- PMID: 31501534
- DOI: 10.1038/s41585-019-0226-y
The multifaceted immune regulation of bladder cancer
Abstract
Bladder cancer is an important public health concern owing to its prevalence, high recurrence risk and treatment failures. Maintaining the equilibrium between prompt and effective immunity and an excessive and protracted immune response is critical for successful immune defence. This delicate balance is ensured by intrinsic or extrinsic immunoregulatory mechanisms. Intrinsic control of immune cell activation is mediated by stimulatory and inhibitory receptors expressed on the effector cell itself, whereas extrinsic control is mediated via other immune cells by cell-cell contact and/or secretion of inhibitory factors. Tumours can exacerbate these immunosuppressive pathways, fostering a tolerant microenvironment. These mechanisms have previously been poorly described in urothelial carcinoma, but a growing body of evidence highlights the key role of immune regulation in bladder cancer. This process includes immune checkpoints (mostly programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1)), as well as regulatory T cells, myeloid-derived suppressor cells, tumour-associated macrophages and type 2 innate and adaptive lymphocytes. For each component, quantitative and qualitative alterations, clinical relevance and potential targeting strategies are currently being explored. An improved understanding of immune regulation pathways in bladder cancer development, recurrence and progression will help in the design of novel diagnostic and prognostic tools as well as treatments.
Similar articles
-
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.J Pathol. 2019 Oct;249(2):151-165. doi: 10.1002/path.5306. Epub 2019 Jun 24. J Pathol. 2019. PMID: 31102277 Free PMC article. Review.
-
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.Urol Oncol. 2017 Jan;35(1):14-20. doi: 10.1016/j.urolonc.2016.10.004. Epub 2016 Nov 3. Urol Oncol. 2017. PMID: 27816403 Review.
-
Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.Nat Rev Urol. 2020 Feb;17(2):77-106. doi: 10.1038/s41585-019-0263-6. Epub 2020 Jan 17. Nat Rev Urol. 2020. PMID: 31953517 Review.
-
Immune checkpoint inhibitors for metastatic bladder cancer.Cancer Treat Rev. 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31. Cancer Treat Rev. 2018. PMID: 29407369 Review.
-
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.Arch Esp Urol. 2018 May;71(4):393-399. Arch Esp Urol. 2018. PMID: 29745928 Review. English, Spanish.
Cited by
-
M2 Macrophage Co-Expression Factors Correlate With Immune Phenotype and Predict Prognosis of Bladder Cancer.Front Oncol. 2021 Mar 22;11:609334. doi: 10.3389/fonc.2021.609334. eCollection 2021. Front Oncol. 2021. PMID: 33828973 Free PMC article.
-
COL6A1 Inhibits the Malignant Development of Bladder Cancer by Regulating FBN1.Cell Biochem Biophys. 2024 Oct 4. doi: 10.1007/s12013-024-01573-6. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 39365515
-
Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer.Cancer Manag Res. 2024 Sep 30;16:1305-1319. doi: 10.2147/CMAR.S467817. eCollection 2024. Cancer Manag Res. 2024. PMID: 39372705 Free PMC article.
-
Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.J Immunother Cancer. 2022 Mar;10(3):e003416. doi: 10.1136/jitc-2021-003416. J Immunother Cancer. 2022. PMID: 35338085 Free PMC article.
-
Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy.Front Oncol. 2022 Mar 2;12:820242. doi: 10.3389/fonc.2022.820242. eCollection 2022. Front Oncol. 2022. PMID: 35311150 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials